During a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions. Read more
Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more
During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more
Investigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
Study provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more
When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more
Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more
During the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more